Arrowhead third-quarter 2010 net reduction decreases to $0.

We have selected already, for diligence and potential acquisition, an exciting technology that addresses the large, underserved obesity market chance. With these achievements, we are making essential strategic advancements to create a robust and unique portfolio of nanomedicine businesses.’ THIRD QUARTER FISCAL 2010 AND RECENT Business HIGHLIGHTS: Business highlights: Arrowhead guaranteed $8.7 million in financing through a registered direct offering of share and warrants. Arrowhead rejoined the Russell Microcap Index. Presented interim data from majority-owned subsidiary Calando Pharmaceuticals, Inc.’s Phase I human being trial of its anti-tumor siRNA therapeutic, CALAA-01, at the American Culture for Clinical Oncology Annual Meeting.The findings, on April 5th which appear on-line in the journal Current Biology, are reported by Laila Partida and Christian Hertweck from the Leibniz Institute for Organic Product Research and Contamination Biology in Jena, Germany. This partnership under study may be the symbiosis of the fungus Rhizopus microsporus and Burkholderia bacterias that live within its cells. Both species effectively synergy to breakdown young rice vegetation for their nutrients, leading to a plant disease referred to as rice seedling blight. History work from the study group had exposed that the Burkholderia bacterias play a critical part in the virulence of the fungus against rice seedlings: The bacteria create a plant poison referred to as rhizoxin, which provides been shown to end up being the causative agent in rice seedling blight.